Skip to content
Strength & muscleRandomised trial3 min read

Protein, leucine and vitamin D formula sped gait recovery in older adults with sarcopenia

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes. · Journal of cachexia, sarcopenia and muscle · 2020 · Original paper ↗

Key takeaway

In a trial of 140 hospitalized older adults with sarcopenia, a whey protein, leucine and vitamin D formula raised gait speed by 0.061 m/s per month versus -0.001 with placebo (difference 0.063 m/s/month, 95% CI 0.043 to 0.082, P < 0.001). It was a single-site trial, and results were analyzed in 127 patients who were reassessed at discharge.

Study design

Randomised trial

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

The research question

Exercise, enough protein and vitamin D are the usual advice for sarcopenia, but the evidence for nutritional support during rehabilitation is thin. The authors tested whether a muscle-targeted formula improves recovery when added to a hospital exercise rehabilitation programme.

Who and how

Single-site, double-blind, randomized controlled trial (NCT03120026; May 2017 to December 2018) of 140 adults aged 65 or older with sarcopenia by the European Working Group on Sarcopenia in Older People 2010 criteria, hospitalized for rehabilitation. They received a whey protein formula enriched with leucine and vitamin D or an iso-caloric control formula twice daily, until discharge (at least 4 weeks and up to 8 weeks), on top of a standard hospital diet. The primary endpoint was change in 4 m gait speed per month; secondary endpoints included chair-stand, timed up and go, short physical performance battery, muscle strength and mass, cognition, quality of life and length of stay.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Of 161 patients screened, 140 were randomized; 13 stopped because they disliked the product (6 experimental, 7 placebo), and analysis covered 127 reassessed at discharge.
  2. 2
    Gait speed rose by 0.061 m/s/month (95% CI 0.043 to 0.080) with the formula (n = 64) versus -0.001 m/s/month (95% CI -0.008 to 0.006) with placebo (n = 63): mean difference 0.063 m/s/month (95% CI 0.043 to 0.082; P < 0.001).
  3. 3
    Muscle mass improved significantly (P < 0.03), as did all key secondary physical performance, functional and cognitive endpoints (P < 0.001 for all).
  4. 4
    More patients in the formula group improved their rehabilitation intensity profile (P = 0.003) and were discharged home (P = 0.002), and rehabilitation (P < 0.001) and hospital stay (P < 0.001) were shorter.

Limits & uncertainty

  1. 1
    One site and 127 analyzed patients means results may not apply to other hospitals or to older people living at home.
  2. 2
    13 participants dropped out because they disliked the product, and the analysis was of reassessed patients, which can affect fairness of the comparison.
  3. 3
    Many secondary and economic outcomes were tested, and length of stay is only a surrogate for cost; the abstract does not report who funded the trial. This reading is based on the abstract only.

What to take from it

For hospitalized older adults, the results suggest that a protein, leucine and vitamin D formula alongside supervised rehabilitation may help recovery of walking speed and function. This is a specific product tested in patients under care, so nutritional supplements should be discussed with the care team, not started on this basis alone.

Reading your own data

Gait speed over a short distance and chair-stand tests are what the trial measured. A phone or watch can give a rough walking speed or step trend, and a strength log of chair-stand repetitions is another way to follow your own progress. Compare readings taken the same way over weeks.

How to read this evidence

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

Sarcopenia is a disease associated with aging and a negative prognosis. Consensus-based treatment consists in targeting muscle mass and function through physical exercise, optimization of protein intake, and vitamin D supplementation, but evidence is lacking. We evaluated the safety and efficacy of a muscle-targeted nutritional support on the outcome of a physical exercise rehabilitation programme.

Methods

In a single-site, double-blind, randomized, controlled trial (NCT03120026; May 2017 to December 2018), old (≥65 years) adults [N = 140 (63% female patients; age, 81 ± 6 years)] without severe cognitive impairment, who were found to have sarcopenia by European Working Group on Sarcopenia in Older People 2010 criteria and hospitalized for physical rehabilitation, were randomized to receive until discharge (for at least 4 weeks and up to 8 weeks) a whey protein-based nutritional formula enriched with leucine and vitamin D or an iso-caloric control formula twice daily in addition to a standard hospital diet. The primary endpoint was the change in 4 m gait speed per month. Key secondary endpoints addressed the change in physical performance: chair-stand test, timed up and go test, and short physical performance battery. Other secondary outcomes were the change in functional status, muscle strength and mass, cognitive status, and quality of life. The proportion of patients who improved their rehabilitation intensity profile and overall economic benefits (using length of stay and duration of rehabilitation as surrogate measures) were also evaluated.

Results

A total of 161 patients were screened and 140 were randomized to study interventions. Thirteen patients (experimental, n = 6; placebo, n = 7) discontinued the intervention because they disliked the product and intention-to-treat analyses were based on patients reassessed at discharge [n = 127 (66% female patients; age, 81 ± 6 years)]. Supplementation with the experimental formula (n = 64) resulted in greater increase in mean gait speed {0.061 m/s/month [95% confidence interval (CI), 0.043 to 0.080]} than placebo [n = 63; -0.001 m/s/month (95%CI, -0.008 to 0.006)]: mean difference, 0.063 m/s/month (95%CI, 0.043 to 0.082) (P < 0.001). A significant effect was also found for muscle mass (P < 0.03) and all key secondary outcomes, functional and cognitive endpoints (P < 0.001 for all). Supplementation resulted also in higher proportion of patients improving their rehabilitation intensity profile (P = 0.003) and being discharged home (P = 0.002); shorter rehabilitation (P < 0.001); and hospital stay (P < 0.001).

Conclusions

In old adults with sarcopenia admitted to hospital for rehabilitation the consumption of a whey protein-based nutritional formula enriched with leucine and vitamin D improved physical performance and function, as well as muscle mass, and reduced the intensity and costs of care.

Sources & attribution

Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes.

Rondanelli M, Cereda E, Klersy C, Faliva MA, Peroni G, Nichetti M, Gasparri C, Iannello G, Spadaccini D, Infantino V, Caccialanza R, Perna S.

Journal of cachexia, sarcopenia and muscle · 2020-09-22

DOI: 10.1002/jcsm.12532 ↗PubMed · 32961041 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Overview of reviews

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

In-depth explainersRead study →
·Trial meta-analysis

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

In-depth explainersRead study →
·Observational meta-analysis

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

In-depth explainersRead study →
·Trial meta-analysis

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

In-depth explainersRead study →
Strength & muscle →